Icon Plc (NASDAQ:ICLR) Given Consensus Rating of “Hold” by Brokerages

Icon Plc (NASDAQ:ICLR) has received an average recommendation of “Hold” from the seventeen analysts that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $148.80.

A number of research firms have issued reports on ICLR. Rothschild & Co Redburn set a $100.00 price target on shares of Icon and gave the stock a “neutral” rating in a research report on Tuesday, February 17th. Leerink Partners reaffirmed a “market perform” rating and issued a $105.00 price objective on shares of Icon in a report on Thursday, February 12th. TD Cowen upgraded shares of Icon from a “hold” rating to a “buy” rating and cut their price objective for the stock from $183.00 to $120.00 in a research note on Wednesday, February 18th. Truist Financial reissued a “hold” rating and set a $222.00 target price (down from $231.00) on shares of Icon in a report on Thursday, January 8th. Finally, Mizuho set a $216.00 target price on shares of Icon in a research report on Friday, January 9th.

Hedge Funds Weigh In On Icon

Several institutional investors and hedge funds have recently modified their holdings of the stock. Sanctuary Advisors LLC grew its holdings in Icon by 1.1% during the fourth quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock worth $899,000 after acquiring an additional 56 shares during the period. Geneos Wealth Management Inc. lifted its holdings in Icon by 11.5% in the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after acquiring an additional 56 shares during the period. Spire Wealth Management lifted its holdings in Icon by 10.1% in the third quarter. Spire Wealth Management now owns 678 shares of the medical research company’s stock valued at $119,000 after acquiring an additional 62 shares during the period. New Wave Wealth Advisors LLC boosted its position in Icon by 5.1% in the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock worth $270,000 after purchasing an additional 72 shares in the last quarter. Finally, Signaturefd LLC grew its stake in shares of Icon by 12.6% during the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock worth $117,000 after purchasing an additional 72 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Trading Down 1.0%

Shares of NASDAQ:ICLR opened at $102.08 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon has a 52-week low of $66.57 and a 52-week high of $211.00. The stock has a market cap of $8.24 billion, a price-to-earnings ratio of 13.81, a PEG ratio of 2.61 and a beta of 1.35. The business has a 50-day moving average price of $126.38 and a 200-day moving average price of $160.20.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.